Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs are medications used to treat viral infections by inhibiting the development of the virus. In Niger, the Antiviral Drugs market has been developing at a steady pace in recent years.
Customer preferences: Niger has a high prevalence of viral infections such as HIV, hepatitis B, and hepatitis C. Therefore, the demand for antiviral drugs is high among the population. However, due to the low purchasing power of the majority of the population, the demand for generic antiviral drugs is higher than branded ones.
Trends in the market: The Antiviral Drugs market in Niger has been growing due to the increasing prevalence of viral infections in the country. The market is dominated by generic drugs due to their affordability. The government has also been taking steps to increase access to antiviral drugs by providing subsidies for the purchase of these drugs. Additionally, there has been a growing trend towards the use of combination therapies, which involve the use of multiple antiviral drugs to increase their effectiveness.
Local special circumstances: Niger is a low-income country with a high burden of infectious diseases. The country faces several challenges in the healthcare sector, including a shortage of healthcare workers, inadequate healthcare infrastructure, and limited access to essential medicines. The government has been working to address these challenges by increasing healthcare spending and investing in healthcare infrastructure.
Underlying macroeconomic factors: Niger has a growing population, which is expected to drive the demand for healthcare services, including antiviral drugs. The country's economy is largely dependent on agriculture, which accounts for over 40% of the country's GDP. However, the agriculture sector is vulnerable to climate change, which can affect the country's economic growth and healthcare spending. Additionally, the country's healthcare sector is heavily reliant on external aid, which can be affected by changes in donor priorities and funding.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
